Clinical trials
Phase 1 clinical trials
Below are recruiting phase 1 clinical trials, each written for real people, not researchers. We’re tracking 286 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04333706RecruitingPhase 1/Phase 2
Sarilumab plus capecitabine for certain breast cancers
This trial studies whether adding sarilumab to capecitabine can shrink or control metastatic or high-risk breast cancer that lacks HER2 and is either triple-negative or hormone-resistant. It aims to find a safe dose first, then look at how well the treatment works compared with historical results.
Los Angeles, CaliforniaAges 18–99 - NCT06527300RecruitingPhase 2
Study of NHWD-870 for advanced NUT cancer
This trial tests a new drug called NHWD-870 for people with NUT cancer (a rare cancer linked to a gene change). The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
ChongqingAges 12–75 - NCT07072234RecruitingPhase 1
CAR NK cell therapy for advanced clear cell kidney cancer
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
Houston, TexasAges 18 years+ - NCT06680232RecruitingPhase 1
Gene therapy trial for chronic hepatitis B
This trial tests a gene therapy called PBGENE-HBV for people with chronic hepatitis B who are already on antiviral treatment. The goal is to see if it is safe and can help control the virus.
Boston, MassachusettsAges 18–70 - NCT07706686RecruitingPhase 1
Dengue challenge study in people with prior infection
This study tests how the body responds to a mild, lab-made dengue virus in people who have had dengue before. It looks at how the immune system reacts to a second infection, which may help improve future vaccines and treatments.
Bethesda, MarylandAges 18–50 - NCT07593092RecruitingPhase 1
Testing new cancer immunotherapy for advanced ovarian cancer
This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.
Lake Success, New YorkAges 18 years+ - NCT06990698RecruitingPhase 1
Testing FP008 in advanced solid tumors
This trial tests an experimental drug called FP008, which may help the immune system fight advanced solid tumors. It is for people whose cancer has continued to grow despite standard treatments or who cannot tolerate them.
Wuhan, HubeiAges 18 years+ - NCT07382726RecruitingPhase 1
Study of izalontamab brengitecan plus adagrasib for KRAS G12C lung cancer
This trial tests a combination of two targeted drugs for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and has stopped responding to a previous KRAS G12C inhibitor. The goal is to see if the combination is safe and works better than the single drug alone.
Houston, TexasAges 18 years+ - NCT07755436RecruitingPhase 1
Study of ARR-002 for advanced ovarian or endometrial cancer
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Irving, TexasAges 18 years+ - NCT04608110RecruitingPhase 1
Novel therapy for myelodysplastic syndrome
This study tests a new combination treatment for people with myelodysplastic syndrome (MDS), a blood disorder. The drug aims to slow the disease and improve blood counts, and might be an option for patients who haven't responded to other treatments.
Bunkyō CityAges 20 years+ - NCT06823167RecruitingPhase 1
Study of IM-1021 for advanced cancers
This trial tests a new drug (IM-1021) for people with advanced cancers like lymphoma or solid tumors who have run out of standard options. The drug targets a protein called ROR1, which is found on some cancer cells, and may help shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT05901285RecruitingPhase 1
Vaccine injected into tumors plus immunotherapy for advanced cancers
This Phase 1 trial tests a cancer vaccine (VAX014) injected directly into a tumor, given alone at first and then with an immune checkpoint medicine (nivolumab or pembrolizumab). It aims to see how well this approach is tolerated and may help shrink advanced solid tumors after other treatments stopped working.
Tucson, ArizonaAges 18 years+ - NCT07543055RecruitingPhase 1
CAR T-Cell Therapy for Advanced Prostate Cancer
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
Hackensack, New JerseyAges 18 years+ - NCT06258408RecruitingPhase 1
BB102 for advanced solid tumors that have not responded to treatment
This trial studies a new drug called BB102 that targets a specific protein (FGF19/FGFR4) found on some cancer cells. It is for people with advanced solid tumors, especially liver cancer, who have run out of standard treatment options. The goal is to see if the drug is safe and helps shrink or control the cancer.
Guangzhou, GuangdongAges 18–78 - NCT05683717RecruitingPhase 1
First-dose test of TT-01488 for B-cell cancers
This Phase 1 study tests whether TT-01488 is safe and tolerable in people with B-cell malignancies (blood cancers). It’s meant for patients whose disease has come back or did not respond after standard treatments.
Nanjing, JiangsuAges 18 years+ - NCT05522868RecruitingPhase 1
Tested drug for solid tumors after standard treatment stopped
This Phase 1 study tests SB17170 in people with solid tumors that have spread or grown despite standard treatments. It looks for safety and early signs of how well the drug might work when other options have failed.
SeoulAges 19 years+ - NCT04093466RecruitingPhase 1
Testing a new pill for advanced solid tumors
This Phase 1 trial tests kanitinib (CX1003), a new cancer medicine, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The goal is to find a safe dose and see early signs of tumor response.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04371900Recruiting
Study children of mothers using birth control access in Michigan
This study looks at children ages 0 to 17 whose mothers took part in a Michigan program to access birth control. Researchers will track child and family outcomes to understand how improving access to contraception can affect families.
Ann Arbor, MichiganAges birth–17 years - NCT07665892RecruitingPhase 1
Testing a new asthma drug in adults
This study tests a new medication called ASY202 for adults with stable asthma. The goal is to see if it's safe and how the body processes it. It may be an option for those who have not had a recent asthma attack or infection.
Glendale, ArizonaAges 18–55 - NCT06465550RecruitingPhase 1
Gene therapy for beta-thalassemia in children and teens
This trial tests a new gene therapy (BD211) for children and teens with severe beta-thalassemia who need regular blood transfusions. The treatment uses your own blood stem cells, modified with a working gene, to help your body make healthy red blood cells and reduce the need for transfusions.
Guangzhou, GuandongAges 3–35 - NCT07533955RecruitingPhase 1
Testing JADE201 drug in rheumatoid arthritis patients
This early-stage study tests a new drug called JADE201 in people with rheumatoid arthritis (RA). Researchers want to see if it is safe and how the body handles it, which could lead to better RA treatments.
Chisinau, MoldovaAges 18–70 - NCT07362888RecruitingPhase 1
Testing a new drug ADCE-B05 for advanced solid tumors
This trial tests a new investigational drug called ADCE-B05 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Springdale, ArkansasAges 18 years+ - NCT07639047RecruitingPhase 1
Testing AN8025 in Advanced Solid Cancers
This early-stage trial tests a new drug called AN8025 in people with advanced solid tumors (cancers that started in organs or tissues). The study aims to find the right dose and see if it helps patients whose cancers have grown despite other treatments.
Nedlands, Western AustraliaAges 18 years+ - NCT06726369RecruitingPhase 1
Study of MK-6204 for people with advanced solid tumors
This trial tests a new drug, MK-6204, in people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
BeijingAges 18 years+
Hear when a new Phase 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 1?
- Yes. Clin2 currently lists 286 recruiting phase 1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.